Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

For more than a decade, Michelle Hobson endured extreme fatigue, excruciating abdominal pain, and repeated hospital visits.

Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...